COMP <GO>
CYRX vs AKTS // EV/EBITDA & P/E VALUATION
CryoPort Inc. (NASDAQ) VS. Aktis Oncology Inc. (NASDAQ) • 15-METRIC TALLY: CYRX 1
— AKTS 1
■ METRIC PARITY
LAST: $18.29 (-1.88%) • MKT CAP: $926.4M
valuation
—
LAST: $16.85 (+0.18%) • MKT CAP: $937.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CYRX VS. AKTS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CYRX | AKTS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 47.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.50% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.70% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -20.90% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 44.40% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 12.40% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.33 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 36.4 | +11.94 | CYRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 9.9x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $926.4M | $937.2M | -$10.8M | AKTS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CYRX REV | AKTS REV | CYRX GROSS % | AKTS GROSS % | CYRX FCF | AKTS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $176.2M | $0 | 47.1% | — | -$25.0M | — |
| FY 2024 | $156.8M | — | 44.4% | — | -$33.6M | — |
| FY 2023 | $168.7M | — | — | — | -$757.0K | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CYRX // BETA —
AKTS // BETA —